Haqqani Maha H, Kester Louis P, Lin Brenda, Farber Alik, King Elizabeth G, Cheng Thomas W, Alonso Andrea, Garg Karan, Eslami Mohammad H, Rybin Denis, Siracuse Jeffrey J
Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, MA.
Division of Vascular and Endovascular Surgery, Department of Surgery, New York University Langone Medical Center, New York, NY.
J Vasc Surg. 2023 Dec;78(6):1479-1488.e2. doi: 10.1016/j.jvs.2023.08.112. Epub 2023 Oct 6.
Revascularization for intermittent claudication (IC) due to infrainguinal peripheral arterial disease (PAD) is dependent on durability and expected benefit. We aimed to assess outcomes for IC interventions in octogenarians and nonagenarians (age ≥80 years) and those younger than 80 years (age <80 years).
The Vascular Quality Initiative was queried (2010-2020) for peripheral vascular interventions (PVIs) and infrainguinal bypasses (IIBs) performed to treat IC. Baseline characteristics, procedural details, and outcomes were analyzed (comparing age ≥80 years and age <80 years).
There were 84,210 PVIs (12.1% age ≥80 years and 87.9% age <80 years) and 10,980 IIBs (7.4% age ≥80 years and 92.6% age <80 years) for IC. For PVI, patients aged ≥80 years more often underwent femoropopliteal (70.7% vs 58.1%) and infrapopliteal (19% vs 9.3%) interventions, and less often iliac interventions (32.1% vs 48%) (P < .001 for all). Patients aged ≥80 years had more perioperative hematomas (3.5% vs 2.4%) and 30-day mortality (0.9% vs 0.4%) (P < .001). At 1-year post-intervention, the age ≥80 years cohort had fewer independently ambulatory patients (80% vs 91.5%; P < .001). Kaplan-Meier analysis showed patients aged ≥80 years had lower reintervention/amputation-free survival (81.4% vs 86.8%), amputation-free survival (87.1% vs 94.1%), and survival (92.3% vs 96.8%) (P < .001) at 1-year after PVI. Risk adjusted analysis showed that age ≥80 years was associated with higher reintervention/amputation/death (hazard ratio [HR], 1.22; 95% confidence interval [CI], 1.1-1.35), amputation/death (HR, 1.85; 95% CI, 1.61-2.13), and mortality (HR, 1.92; 95% CI, 1.66-2.23) (P < .001 for all) for PVI. For IIB, patients aged ≥80 years more often had an infrapopliteal target (28.4% vs 19.4%) and had higher 30-day mortality (1.3% vs 0.5%), renal failure (4.1% vs 2.2%), and cardiac complications (5.4% vs 3.1%) (P < .001). At 1 year, the age ≥80 years group had fewer independently ambulatory patients (81.7% vs 88.8%; P = .02). Kaplan-Meier analysis showed that the age ≥80 years cohort had lower reintervention/amputation-free survival (75.7% vs 81.5%), amputation-free survival (86.9% vs 93.9%), and survival (90.4% vs 96.5%) (P < .001 for all). Risk-adjusted analysis showed age ≥80 years was associated with higher amputation/death (HR, 1.68; 95% CI, 1.1-2.54; P = .015) and mortality (HR, 1.85; 95% CI, 1.16-2.93; P = .009), but not reintervention/amputation/death (HR, 1.1; 95% CI, 0.85-1.44; P = .47) after IIB.
Octogenarians and nonagenarians have greater perioperative morbidity and long-term ambulatory impairment, limb loss, and mortality after PVI and IIB for claudication. Risks of intervention on elderly patients with claudication should be carefully weighed against the perceived benefits of revascularization. Medical and exercise therapy efforts should be maximized in this population.
因下肢周围动脉疾病(PAD)导致间歇性跛行(IC)的血运重建取决于其耐久性和预期获益。我们旨在评估80岁及以上(年龄≥80岁)和80岁以下(年龄<80岁)人群IC干预的结果。
查询血管质量改进计划(2010 - 2020年)中为治疗IC而进行的外周血管介入治疗(PVI)和股腘以下旁路移植术(IIB)。分析基线特征、手术细节和结果(比较年龄≥80岁和年龄<80岁)。
共有84210例PVI(年龄≥80岁者占12.1%,年龄<80岁者占87.9%)和10980例IIB(年龄≥80岁者占7.4%,年龄<80岁者占92.6%)用于治疗IC。对于PVI,年龄≥80岁的患者更常接受股腘动脉(70.7%对58.1%)和腘以下动脉(19%对9.3%)介入治疗,而髂动脉介入治疗较少(32.1%对48%)(所有P<0.001)。年龄≥80岁的患者围手术期血肿更多(3.5%对2.4%),30天死亡率更高(0.9%对0.4%)(P<0.001)。干预后1年,年龄≥80岁的队列中能够独立行走的患者较少(80%对91.5%;P<0.001)。Kaplan-Meier分析显示,年龄≥80岁的患者在PVI后1年的再次干预/无截肢生存率较低(81.4%对86.8%)、无截肢生存率较低(87.1%对94.1%)和生存率较低(92.3%对96.8%)(P<0.001)。风险调整分析显示,年龄≥80岁与PVI后更高的再次干预/截肢/死亡风险(风险比[HR],1.22;95%置信区间[CI],1.1 - 1.35)、截肢/死亡风险(HR,1.85;95% CI,1.61 - 2.13)和死亡风险(HR,1.92;95% CI,1.66 - 2.23)相关(所有P<0.001)。对于IIB,年龄≥80岁的患者更常以腘以下动脉为目标(28.4%对19.4%),30天死亡率更高(1.3%对0.5%)、肾衰竭发生率更高(4.1%对2.2%)和心脏并发症发生率更高(5.4%对3.1%)(P<0.001)。1年时,年龄≥80岁组能够独立行走的患者较少(81.7%对88.8%;P = 0.02)。Kaplan-Meier分析显示,年龄≥80岁的队列再次干预/无截肢生存率较低(75.7%对81.5%)、无截肢生存率较低(86.9%对93.9%)和生存率较低(90.4%对96.5%)(所有P<0.001)。风险调整分析显示,年龄≥80岁与IIB后更高的截肢/死亡风险(HR,1.68;95% CI,1.1 - 2.54;P = 0.015)和死亡风险(HR,1.85;95% CI,1.16 - 2.93;P = 0.009)相关,但与再次干预/截肢/死亡风险无关(HR,1.1;95% CI,0.85 - 1.44;P = 0.47)。
80岁及以上人群在因间歇性跛行进行PVI和IIB后,围手术期发病率更高,长期存在行走功能障碍、肢体缺失和死亡风险。对于老年间歇性跛行患者进行干预的风险应与血运重建的预期获益仔细权衡。应在该人群中最大限度地进行药物和运动治疗。